Abstract: Diffuse large B-cell lymphoma (DLBCL) is one of the most common hematologic malignancies, and the conventional application of Rituximab in combination with cyclophosphamide + adriamycin + vincristine + prednisone treatment regimen has increased the cure rate of DLBCL, but the prognosis varies widely among patients. The current methods for predicting prognosis have some limitations. ¹⁸F-fluorodeoxyglucose (FDG) PET/CT has been widely used in the diagnosis and treatment of DLBCL, and its metabolic parameter metabolic tumor volume (MTV) is a strong predictor. However, there are still some controversies on how to better apply MTV in clinical practice. This paper reviews the research progress of MTV in predicting the prognosis of DLBCL.